These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 38216911)
21. Neuroinflammation and protein pathology in Parkinson's disease dementia. Kouli A; Camacho M; Allinson K; Williams-Gray CH Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323 [TBL] [Abstract][Full Text] [Related]
22. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. Jan A; Gonçalves NP; Vaegter CB; Jensen PH; Ferreira N Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361100 [TBL] [Abstract][Full Text] [Related]
23. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments. Sanchez-Guajardo V; Tentillier N; Romero-Ramos M Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748 [TBL] [Abstract][Full Text] [Related]
24. Loss of cannabinoid receptor 2 promotes α-Synuclein-induced microglial synaptic pruning in nucleus accumbens by modulating the pCREB-c-Fos signaling pathway and complement system. Feng L; Lo H; You H; Wu W; Cheng X; Xin J; Ye Z; Chen X; Pan X Exp Neurol; 2023 Jan; 359():114230. PubMed ID: 36162511 [TBL] [Abstract][Full Text] [Related]
25. Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD. Iba M; McDevitt RA; Kim C; Roy R; Sarantopoulou D; Tommer E; Siegars B; Sallin M; Kwon S; Sen JM; Sen R; Masliah E Mol Neurodegener; 2022 Sep; 17(1):60. PubMed ID: 36064424 [TBL] [Abstract][Full Text] [Related]
26. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment. Kalsoom I; Wang Y; Li B; Wen H Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991 [TBL] [Abstract][Full Text] [Related]
27. FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis. Choi YR; Kang SJ; Kim JM; Lee SJ; Jou I; Joe EH; Park SM Neurobiol Dis; 2015 Nov; 83():90-9. PubMed ID: 26342897 [TBL] [Abstract][Full Text] [Related]
28. Evolving insights into erythrocytes in synucleinopathies. Yang Y; Nie X; Wang Y; Sun J; Gao X; Zhang J Trends Neurosci; 2024 Sep; 47(9):693-707. PubMed ID: 39043489 [TBL] [Abstract][Full Text] [Related]
29. The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease. Battis K; Xiang W; Winkler J Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686080 [TBL] [Abstract][Full Text] [Related]
30. Tilorone mitigates the propagation of α-synucleinopathy in a midbrain-like organoid model. Zhang Q; Liu M; Xu Y; Lee J; Jones B; Li B; Huang W; Ye Y; Zheng W J Transl Med; 2024 Sep; 22(1):816. PubMed ID: 39223664 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665 [TBL] [Abstract][Full Text] [Related]
32. Plasma exosomes impair microglial degradation of α-synuclein through V-ATPase subunit V1G1. Li Y; Wang Y; Kou L; Yin S; Chi X; Sun Y; Wu J; Jin Z; Zhou Q; Zou W; Wang T; Xia Y CNS Neurosci Ther; 2024 May; 30(5):e14738. PubMed ID: 38702933 [TBL] [Abstract][Full Text] [Related]
33. T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils. George S; Tyson T; Rey NL; Sheridan R; Peelaerts W; Becker K; Schulz E; Meyerdirk L; Burmeister AR; von Linstow CU; Steiner JA; Galvis MLE; Ma J; Pospisilik JA; Labrie V; Brundin L; Brundin P J Parkinsons Dis; 2021; 11(2):585-603. PubMed ID: 33579871 [TBL] [Abstract][Full Text] [Related]
34. Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions. Tanriöver G; Bacioglu M; Schweighauser M; Mahler J; Wegenast-Braun BM; Skodras A; Obermüller U; Barth M; Kronenberg-Versteeg D; Nilsson KPR; Shimshek DR; Kahle PJ; Eisele YS; Jucker M Acta Neuropathol Commun; 2020 Aug; 8(1):133. PubMed ID: 32787922 [TBL] [Abstract][Full Text] [Related]
35. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. Sanchez-Guajardo V; Febbraro F; Kirik D; Romero-Ramos M PLoS One; 2010 Jan; 5(1):e8784. PubMed ID: 20098715 [TBL] [Abstract][Full Text] [Related]
36. The 'α-synucleinopathy syndicate': multiple system atrophy and Parkinson's disease. Sian-Hulsmann J; Riederer P J Neural Transm (Vienna); 2024 Jun; 131(6):585-595. PubMed ID: 37227594 [TBL] [Abstract][Full Text] [Related]
37. Microglia in Parkinson's Disease. Stefanova N J Parkinsons Dis; 2022; 12(s1):S105-S112. PubMed ID: 35754289 [TBL] [Abstract][Full Text] [Related]
39. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease. Park JY; Paik SR; Jou I; Park SM Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945 [TBL] [Abstract][Full Text] [Related]
40. α-Synuclein and Glia in Parkinson's Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System? Filippini A; Gennarelli M; Russo I Cell Mol Neurobiol; 2019 Mar; 39(2):161-168. PubMed ID: 30637614 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]